Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
The CAR3: Study Day for Haematology Nurses took place virtually on 25 September. Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the hematological oncology field. But despite their benefits, CAR T-cell therapies come with high risk for serious adverse events. Nurses play a critical role in monitoring and managing adverse events related to CAR-T therapy.
Additionally, oncology nurses are crucial in educating patients and caregivers on CAR T-cell therapy.
Therefore, it is essential to educate nurses to maintain their knowledge and skills in a complex and evolving setting and deliver safe, quality patient care.
At the meeting, presentation topics included the science of CAR T-cells, UK patient data, ITU and the ward as well as palliative care for CAR-T patients. The role of pharmacy, CAR-T toxicities and psychological support of patients were also discussed.
Watch the full series of presentations from the meeting below.